PGNY

Leerink Partners Initiates Coverage of Progyny (PGNY) with Outperform Recommendation

Fintel reports that on February 26, 2024, Leerink Partners initiated coverage of Progyny (NasdaqGS:PGNY) with a Outperform recommendation.

Analyst Price Forecast Suggests 23.09% Upside

As of February 24, 2024, the average one-year price target for Progyny is 47.60. The forecasts range from a low of 45.45 to a high of $51.45. The average price target represents an increase of 23.09% from its latest reported closing price of 38.67.

See our leaderboard of companies with the largest price target upside.

The projected annual revenue for Progyny is 1,344MM, an increase of 30.11%. The projected annual non-GAAP EPS is 0.67.

What is the Fund Sentiment?

There are 709 funds or institutions reporting positions in Progyny. This is an increase of 5 owner(s) or 0.71% in the last quarter. Average portfolio weight of all funds dedicated to PGNY is 0.46%, a decrease of 2.19%. Total shares owned by institutions increased in the last three months by 6.23% to 121,051K shares. PGNY / Progyny, Inc. Put/Call Ratios The put/call ratio of PGNY is 1.27, indicating a bearish outlook.

What are Other Shareholders Doing?

PGNY / Progyny, Inc. Shares Held by Institutions

Tpg Gp A holds 6,598K shares representing 6.88% ownership of the company. No change in the last quarter.

International Assets Investment Management holds 5,876K shares representing 6.13% ownership of the company. In it's prior filing, the firm reported owning 2K shares, representing an increase of 99.97%. The firm increased its portfolio allocation in PGNY by 161.93% over the last quarter.

KPCB XIII Associates holds 5,075K shares representing 5.30% ownership of the company. No change in the last quarter.

Clearbridge Investments holds 3,492K shares representing 3.64% ownership of the company. In it's prior filing, the firm reported owning 3,941K shares, representing a decrease of 12.83%. The firm decreased its portfolio allocation in PGNY by 34.54% over the last quarter.

Jpmorgan Chase holds 3,199K shares representing 3.34% ownership of the company. In it's prior filing, the firm reported owning 2,458K shares, representing an increase of 23.15%. The firm decreased its portfolio allocation in PGNY by 86.20% over the last quarter.

Progyny Background Information
(This description is provided by the company.)

Progyny is a leading fertility benefits management company in the US. The company is redefining fertility and family building benefits, proving that a comprehensive and inclusive fertility solution can simultaneously benefit employers, patients, and physicians.

Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.

Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.

Click to Learn More

This story originally appeared on Fintel.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.